CD19 and diffuse large B-cell lymphoma: <h4>Objective</h4>To retrospectively analyze the efficacy and safety of zanubrutinib and camrelizumab combined with CD19 chimeric antigen receptor T-cell (CD19 CAR T-cell) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).<h4>Methods</h4>Thirty-six R/R DLBCL patients who received zanubrutinib and camrelizumab combined with CD19 CAR T-cell from January 2022 to June 2024 were selected in the combined group.